HIV-1 Infection: Clinical Trials

76 trials for HIV-1 Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

58 completed, 5 terminated, 4 active not recruiting, 4 unknown. 76 Phase 2, 10 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 276Completed 58, Terminated 5, Active not recruiting 4, Unknown 4, Withdrawn 3, Recruiting 2
Phase 110Completed 9, Active not recruiting 1
Phase 31Active not recruiting 1

Follow HIV-1 Infection: new trials by email Literature Review of HIV-1 Infection trials Research Report on HIV-1 Infection

Trials (filtered) newest first · largest first

All 76 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
B/F/TAF, GS-3242, Lenacapavir - HIV-1 Infection
Phase 2RecruitingGilead Sciences1252026-10-012026-10-23
A Phase Ⅱa Clinical Study of CL-197 Capsules
CL-197 capsules - HIV-1 Infection
Phase 2RecruitingHenan Genuine Biotech Co., Ltd.242025-11-292026-01-06
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
UB-421 - Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Phase 2WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2025-07-102025-07-11
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
Pomalidomide 2 mg, Placebo, Aspirin 75 mg - HIV-1 Infection
Phase 1 / Phase 2Active not recruitingUniversity of Aarhus322025-05-132026-05-07
UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
UB-421, Optimized background therapy (OBT) - HIV-1 Infection
Phase 2UnknownUnited BioPharma102023-12-012023-04-24
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection
Phase 2Active not recruitingGilead Sciences832023-05-152026-04-27
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
UB-421, chidamide - HIV-1 Infection
Phase 2CompletedUnited BioPharma112021-12-022023-02-15
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
ISL, LEN, B/F/TAF - HIV-1 Infection
Phase 2Active not recruitingGilead Sciences1422021-10-052026-02-04
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Islatravir, Ulonivirine, BIC/FTC/TAF - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC1612021-03-092026-01-26
Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)
DOR/ISL - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC422020-11-262024-01-31
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
UB-421, Antiretroviral Therapy (ART) - HIV-1 Infection
Phase 2WithdrawnUnited BioPharma2020-04-012020-02-21
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
Islatravir, Placebo - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC2422019-09-192025-07-18
A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
Cal-1 (LVsh5/C46) drug product - HIV-1 Infection
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris22019-01-152025-11-20
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients
UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W - HIV-1 Infection
Phase 2CompletedUnited BioPharma312018-12-122022-05-13
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
Islatravir, Placebo to Islatravir, Doravirine - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC1232017-11-272023-03-29
Early ART to Limit Infection and Establishment of Reservoir
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy - HIV-1 Infection
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1952017-01-242025-08-29
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS) - HIV-1 Infection
Phase 2 / Phase 3Active not recruitingGilead Sciences1772016-09-212026-09-24
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Visbiome Extra Strength, Placebo - HIV-1 Infection
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections932016-04-012020-01-06
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C
Phase 2TerminatedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections72016-02-172018-05-02
Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)
Doravirine/lamivudine/tenofovir disoproxil fumarate - HIV-1 Infection
Phase 2CompletedMerck Sharp & Dohme LLC102016-01-142021-10-26

Showing 20 of 76. Sign in to see all of them.

Narrower conditions

Infections (4)  ·  HIV Infections (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Hepatitis C (2)  ·  Inflammation (2)  ·  Cardiovascular Diseases (1)  ·  Lymphoma (1)  ·  Thrombosis (1)  ·  Tuberculosis (1)

Broader conditions

Blood-Borne Infections (7)  ·  Communicable Diseases (7)  ·  Infections (7)  ·  RNA Virus Infections (7)  ·  Virus Diseases (7)  ·  Immune System Diseases (6)  ·  Genital Diseases (5)  ·  Immunologic Deficiency Syndromes (5)  ·  Lentivirus Infections (5)  ·  Retroviridae Infections (5)  ·  Sexually Transmitted Diseases (5)  ·  Sexually Transmitted Diseases, Viral (5)  ·  Urogenital Diseases (5)  ·  Digestive System Diseases (2)  ·  Flaviviridae Infections (2)

Interventions

Ritonavir (8)  ·  Lamivudine (7)  ·  UB-421 (6)  ·  bictegravir, emtricitabine, tenofovir alafenamide, drug combination (5)  ·  dolutegravir (5)  ·  efavirenz (5)  ·  Aspirin (4)  ·  Atazanavir Sulfate (4)  ·  Darunavir (4)  ·  islatravir (4)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (3)  ·  Tenofovir (3)  ·  doravirine (3)  ·  lenacapavir (3)  ·  3BNC117 antibody (2)

Sponsors

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (20)  ·  Gilead Sciences (8)  ·  ANRS, Emerging Infectious Diseases (5)  ·  Merck Sharp & Dohme LLC (5)  ·  United BioPharma (5)  ·  Bionor Immuno AS (3)  ·  Rockefeller University (2)  ·  Tobira Therapeutics, Inc. (2)  ·  University Health Network, Toronto (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Bristol-Myers Squibb (1)  ·  Castagna Antonella (1)  ·  Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1)  ·  GlaxoSmithKline (1)  ·  Henan Genuine Biotech Co., Ltd. (1)

Countries

United States (44)  ·  France (16)  ·  Puerto Rico (13)  ·  South Africa (7)  ·  Canada (6)  ·  Italy (5)  ·  Spain (5)  ·  Thailand (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Germany (4)  ·  Kenya (3)  ·  Peru (3)  ·  Taiwan (3)  ·  Botswana (2)

Top investigators

Christine Katlama, MD (2)  ·  Marina Caskey, MD (2)  ·  Meagan O'Brien, MD (2)  ·  Netanya Sandler, MD (2)  ·  Rajesh Gandhi, MD (2)  ·  Rupert Kaul, MD (2)  ·  Adriana Andrade, MD, MPH (1)  ·  Adriano Lazzarin, Prof (1)  ·  Allan R. Tenorio, M.D. (1)  ·  Amneris E Luque, M.D. (1)  ·  Andrew Beelen, MD (1)  ·  Annie Luetkemeyer, MD (1)  ·  Babafemi Taiwo, MBBS (1)

Results publications

PMID 20710052, PMID 21317794, PMID 21486960, PMID 21811136, PMID 22837004, PMID 23797691, PMID 23830355, PMID 23875707, PMID 24446523, PMID 24620025, PMID 24864123, PMID 25214516, PMID 25624326, PMID 25979307, PMID 26060295, PMID 26075752, PMID 26271944, PMID 26636929, PMID 26684819, PMID 26762988, PMID 27077673, PMID 27965866, PMID 28219610, PMID 28340570, PMID 28714868, PMID 28832406, PMID 29091342, PMID 29253097, PMID 29794828, PMID 30239650, PMID 30535188, PMID 30668695, PMID 30699178, PMID 30830886, PMID 30995373, PMID 31085814, PMID 31425317, PMID 31498109, PMID 31504342, PMID 32661003, PMID 33323024, PMID 33382405, PMID 33540481, PMID 33568510, PMID 34000227, PMID 34049356, PMID 34302760, PMID 34369424, PMID 34693932, PMID 34693933

NIH funding

U01AI068636 (10), UM1AI068636 (7), 2015 (3), 2UM1AI068636 (3), 2019 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2017 (1), R01AI066992 (1), R56HL127995 (1), U01AI095052 (1), U01AI118536 (1)